Abstract

Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules

Author(s): Allen Loyd V Jr

Issue: May/Jun 2014 - Volume 18, Number 3

Page(s): 233

Download in electronic PDF format for $75
  • Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules Page 1

Abstract

A formulation for preparing Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • bumetanide
  • formulation
  • diuretic
  • edema
  • fluid retention
  • congestive heart failure
  • liver disease
  • kidney disease

Related Categories

  • FORMULATIONS
  • GASTROENTEROLOGY
  • CARDIOLOGY
  • UROLOGY/URINARY TRACT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2014
Pg. 233
Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Jan/Feb 2014
Pg. 61
Bumetanide 0.25-mg/mL Injection
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
Sep/Oct 2009
Pg. 367-371
Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret
Author(s): Williams LaVonn A, Riley Kari
Mar/Apr 2010
Pg. 108-111
Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Author(s): Bramwell Bethany L
May/Jun 2013
Pg. 230
Estradiol 0.5-mg, 1-mg, or 2-mg Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2017
Pg. 496
Spironolactone 5 mg/mL in SuspendIt Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2022
Pg. 248-254
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Author(s): Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
Sep/Oct 2010
Pg. 382-394
Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Author(s): Meadows Richard L, Muller George
Mar/Apr 2014
Pg. 142
Doxazosin 1-mg, 2-mg, 4-mg, or 8-mg Capsules
Author(s): Allen Loyd V Jr
May/Jun 2014
Pg. 241
Thiothixene 1-mg, 2-mg, 5-mg, or 10-mg Capsules
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 414-417
Stability of Furosemide 5 mg/mL in Polypropylene Syringes
Author(s): van der Schaar JAJ, Grouls R, Franssen EJF, Crul M
Mar/Apr 2016
Pg. 145
Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules
Author(s): Allen Loyd V Jr
Jan/Feb 2002
Pg. 16-18
Compounding for Diseases of the Oral Cavity: A discussion with Stu Sommerville, RPh
Author(s): Vail Jane
May/Jun 2006
Pg. 227
Quinapril 1-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 333
Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg
Author(s): Allen Loyd V
Sep/Oct 2022
Pg. 436-439
Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease
Author(s): Kobayashi Shunsuke, Ogawara Yuka, Imamura Yoshihiko, Kitaoka Akira, Yasu Takeo